Cost-Effectiveness of Denosumab Versus Zoledronic Acid in the Management of Skeletal Metastases Secondary to Breast Cancer-Reference-Cited by-同舟云学术

Cost-Effectiveness of Denosumab Versus Zoledronic Acid in the Management of Skeletal Metastases Secondary to Breast Cancer

Published:2012-06 Issue:6 Volume:34 Page:1334-1349
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Snedecor Sonya J.,Carter John A.,Kaura Satyin,Botteman Marc F.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference60 articles.

1. Surveillance, Epidemiology and End Results Cancer Statistics Review, 1975–2008;Howlander,2011

2. Anti-transforming growth factor ss antibody treatment rescues bone loss and prevents breast cancer metastasis to bone;Biswas;PLoS One,2011

3. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007);Yong;Breast Cancer Res Treat,2011

4. Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity;Major;BMC Cancer,2009

5. Systematic review of the clinical effectiveness and cost effectiveness and economic evaluation of denosumab for the treatment of bone metastases from solid tumors;Ford,2011

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness Analysis of Denosumab in the Prevention of Skeletal-Related Events Among Patients With Breast Cancer With Bone Metastasis in India;JCO Global Oncology;2024-03

2. Adjuvant zoledronic acid therapy for postmenopausal women with early breast cancer in China: a cost-effectiveness analysis;International Journal for Quality in Health Care;2023-03-27

3. Bone-modifying Agents (BMAs) in Breast Cancer;Clinical Breast Cancer;2021-10

4. Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer;Current Oncology;2021-05-13

5. Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States;Journal of Medical Economics;2019-08-26